Therefore, the UTX inhibitor GSK-J4 is able to reduce the endogenous levels of LIF in osteosarcoma cells through in combination of epigenetic signals that affect NOTCH1 signaling, including an increase of H3K27me3 and a decrease in H3K27ac at LIF gene locus. The gene discussed is LIF; the disease is osteosarcoma.